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Glucocorticoid therapy-induced memory deficits: acute versus
chronic effects
Abstract
Conditions with chronically elevated glucocorticoid levels are usually associated with declarative
memory deficits. Considerable evidence suggests that long-term glucocorticoid exposure may cause
cognitive impairment via cumulative and long-lasting influences on hippocampal function and
morphology. However, because elevated glucocorticoid levels at the time of retention testing are also
known to have direct impairing effects on memory retrieval, it is possible that such acute hormonal
influences on retrieval processes contribute to the memory deficits found with chronic glucocorticoid
exposure. To investigate this issue, we examined memory functions and hippocampal volume in 24
patients with rheumatoid arthritis who were treated either chronically (5.3 +/- 1.0 years, mean +/- SE)
with low to moderate doses of prednisone (7.5 +/- 0.8 mg, mean +/- SE) or without glucocorticoids. In
both groups, delayed recall of words learned 24 h earlier was assessed under conditions of either
elevated or basal glucocorticoid levels in a double-blind, placebo-controlled crossover design. Although
the findings in this patient population did not provide evidence for harmful effects of a history of
chronic prednisone treatment on memory performance or hippocampal volume per se, acute prednisone
administration 1 h before retention testing to either the steroid or nonsteroid group impaired word recall.
Thus, these findings indicate that memory deficits observed under chronically elevated glucocorticoid
levels result, at least in part, from acute and reversible glucocorticoid effects on memory retrieval.
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Conditionswith chronically elevatedglucocorticoid levels areusually associatedwithdeclarativememorydeficits. Considerable evidence
suggests that long-term glucocorticoid exposure may cause cognitive impairment via cumulative and long-lasting influences on hip-
pocampal function and morphology. However, because elevated glucocorticoid levels at the time of retention testing are also known to
have direct impairing effects onmemory retrieval, it is possible that such acute hormonal influences on retrieval processes contribute to
the memory deficits found with chronic glucocorticoid exposure. To investigate this issue, we examined memory functions and hip-
pocampal volume in 24 patients with rheumatoid arthritis who were treated either chronically (5.3 1.0 years, mean SE) with low to
moderate doses of prednisone (7.5 0.8mg,mean SE) orwithout glucocorticoids. In both groups, delayed recall ofwords learned 24 h
earlier was assessed under conditions of either elevated or basal glucocorticoid levels in a double-blind, placebo-controlled crossover
design. Although the findings in this patient population did not provide evidence for harmful effects of a history of chronic prednisone
treatment onmemory performance or hippocampal volumeper se, acute prednisone administration 1 hbefore retention testing to either
the steroid or nonsteroid group impaired word recall. Thus, these findings indicate that memory deficits observed under chronically
elevated glucocorticoid levels result, at least in part, from acute and reversible glucocorticoid effects on memory retrieval.
Key words: glucocorticoids; prednisone; memory; retrieval; hippocampus; MRI
Introduction
Sustained endogenous hypercortisolemia, such as found in de-
pression, Cushing’s disease or human aging, is often associated
with declarative memory impairment (Rubinow et al., 1984;
Starkman et al., 1992; Seeman et al., 1997; Lupien et al., 1998).
Moreover, prolonged glucocorticoid therapy, which is widely
used in clinical practice, is known to induce cognitive deficits
(Keenan et al., 1996; Wolkowitz et al., 1997; Brown et al., 2004;
Bermond et al., 2005; Brunner et al., 2005). Animal and human
studies investigating the neurobiological basis of such memory
deficits suggested that chronic exposure to glucocorticoids can
cause declarative memory impairment via cumulative and long-
lasting detrimental influences on hippocampal function, includ-
ing altered adrenal steroid receptor density, neurotransmitter
content and dendritic atrophy (Starkman et al., 1992; Sapolsky,
2000; Joe¨ls, 2001; McEwen, 2001; Brown et al., 2004). However,
because in studies investigating the effects of chronic glucocorti-
coid exposure memory testing also takes place under conditions
of elevated glucocorticoid levels, it is possible that direct influ-
ences of glucocorticoids on cognitive performance contribute to
these memory deficits. Whereas acutely administered glucocor-
ticoids are known to dose-dependently enhancememory consol-
idation (Roozendaal, 2000; Buchanan and Lovallo, 2001), it is
well established that acutely elevated glucocorticoid levels at the
time of retention testing impair the retrieval of previously ac-
quired information (DeQuervain et al., 1998, 2000, 2003;Wolf et
al., 2001; Het et al., 2005; Buchanan et al., 2006). For example, we
have shown previously that a single administration of cortisone
(25 mg) 1 h before retention testing impairs free recall of words
that have been learned 24 h earlier (De Quervain et al., 2000).
Such acute effects of glucocorticoids on memory retrieval are
limited to the time that circulating hormone levels are elevated
(De Quervain et al., 1998) and known to involve the hippocam-
pus (De Quervain et al., 2003; Roozendaal et al., 2003; Oei et al.,
2007). To investigate whether such acute glucocorticoid effects
on memory retrieval processes are involved in mediating the
memory deficits observed in conditions of chronic glucocorti-
coid excess, we assessedmemory functions and hippocampal vol-
ume in patientswith rheumatoid arthritis whowere treated either
chronically with prednisone at low to moderate and widely used
doses (Bijlsma et al., 2005) or without glucocorticoids and then
manipulated glucocorticoid levels shortly before retention
testing.
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Materials andMethods
Subjects
Twenty-fourmale (n 8) and female (n 16) patients with rheumatoid
arthritis according to the diagnostic criteria of the American College of
Rheumatology (mean disease duration in months  SE, 160.3  26.4,
range 24–516), aged 41–65 years (mean SE, 55.2 1.6) participated in
this study. The inclusion criterion for the group treated chronically with
prednisone (steroid group; n 13) was a continuous und current daily
prednisone medication (between 5 and 15 mg) for at least 1 year. The
nonsteroid group (n 11) consisted of patients without or only sporadic
lifetime glucocorticoid use (i.e., not within the last 6 months) and was
matched to the steroid group on disease activity as measured with the
Disease Activity Score (Prevoo et al., 1995) and the Rheumatoid Arthritis
Disease Activity Index (Stucki et al., 1995) and duration. The therapy of
these patients was based on disease modifying anti-rheumatic drugs,
including tumor necrosis factor- blockers, and nonsteroidal anti-
inflammatory drugs. The decision to use steroid medication or disease
modifying anti-rheumatic drugs was based on doctor’s and/or patient’s
preference (personal risk–benefit analysis). Exclusion criteria for both
groups were psychiatric or neurological disease according to the Inter-
national Statistical Classification of Diseases, 10th revision, severe so-
matic disease other than rheumatoid arthritis, psychotropic medication,
or contraindication for magnetic resonance imaging (MRI). Subjects
gave written informed consent to participate in the study, and all meth-
ods and experimental procedures were approved by the ethical commit-
tee of the University of Zu¨rich, Switzerland.
Procedure and measurements
We used a placebo-controlled, double-blind, crossover design. Immedi-
ately after arrival to the laboratory on day 1, the steroid group took the
daily prednisone dose and the nonsteroid group received 5 mg of pred-
nisone (Prednison Streuli Pharma, Uznach, Switzerland) to produce
similar circulating glucocorticoid levels at learning and during memory
consolidation (Fig. 1). One hour later, subjects were presented a list of 60
unrelated German nouns (De Quervain et al., 2000). The words were
presented (each word for 4 s) twice in a different order on a computer
screen with the instruction to learn them for delayed recall testing. There
was no further prednisone medication in either group until retention
testing 24 h after learning. At that time, the steroid group received either
prednisone at the usual daily dose or a similar looking placebo, and the
nonsteroid group received either 5 mg of prednisone or placebo. One
hour later, free recall was tested for which subjects were asked to write
down all the words they could remember (see Fig. 1). After this delayed
free-recall test, an immediate recall test was performed with another set
of 20 words, which was only presented once. After a 2 week wash-out
period, during which patients continued with their usual treatment reg-
imen, the procedure was repeated in the same individuals with other sets
of words and with the study medication they had not received the first
time (in a double-blind manner). The order of the study medication was
balanced across subjects. All learning and testing procedures were per-
formed between 1:00 P.M. and 4:00 P.M.
Salivary cortisol
Saliva for hormone measurement was sampled on day 2 before the acute
administration of the study medication (prednisone or placebo) and 1 h
later immediately before retention testing with the Salivette sampling
device (Sarstedt, Nuembrecht, Germany). Cortisol was analyzed using a
commercially available immunoassay (CLIA; IBL, Hamburg, Germany).
MRI hippocampus volumetry
MRI Acquisition. Subjects were examined on a
1.5 T MRI system (General Electric, Fairfield,
CT) within 4 weeks after memory testing. T1-
weighted [three-dimensional spoiled gradient
echo; repetition time (TR), 35 ms; echo time
(TE), 9 ms; flip angle, 30°; matrix, 256  256
mm; field of view, 240 mm; slice thickness, 0.8
mm] images (124 slices obtained in sagittal
plane) were used for volumetry. Additional
structural imaging included axial proton
density- and T2-weighted double-echo fast
spin-echo sequences (TR, 3500 ms; TE, 12/102 ms; 2 numbers of excita-
tions; slice thickness/gap, 4/1 mm).
Volumetric analysis. Manual volumetric measurements were per-
formed by one of the authors (O.T.W.), whowas blindwith respect to the
treatment of the patients (i.e., steroid or nonsteroid group), using meth-
ods with previously published high reliability and validity (Convit et al.,
1999; Bobinski et al., 2000; Lobnig et al., 2006). In brief, reformatted
coronal images (1.5 mm slice thickness) were used. The hippocampus
(cornu ammonis, dentate gyrus, and subiculum) was measured in its
entire extension using multiple image orientations (Lobnig et al., 2006).
A cerebral vault volume was obtained by measuring the compartment
bounded by the dura and the tentorium cerebri on every tenth slice
(Lobnig et al., 2006). Ameasure of global CSF, and thus of global cerebral
atrophy, was determined using a threshold procedure (Lobnig et al.,
2006).
Statistics
Group differences in demographic and clinical characteristics were ana-
lyzed with unpaired t tests. Chronic and acute treatment effects on im-
mediate and delayed recall were analyzed with repeated-measures ANO-
VAs with chronic treatment (prednisone vs steroid-free medication) as a
between-subject factor and acute administration of study medication at
the time of retention testing (prednisone vs placebo) as a within-subject
factor. As the two treatment groups significantly differed in age, we in-
cluded age as covariate. Group differences in brain volumes and salivary
cortisol concentrations were analyzed with ANCOVAs with age as
covariate.
Results
The steroid and nonsteroid groups differed significantly in age,
with patients treated without prednisone being younger (Table
1). This difference may reflect the trend toward less steroidal
therapy over the last decade. Otherwise, there were no significant
differences in demographic or clinical data between the two
groups (Table 1).
The ANOVA for delayed recall with chronic treatment (pred-
nisone vs steroid-free medication) as a between-subject factor
and acute administration of study medication at testing (pred-
nisone vs placebo) as awithin-subject factor revealed a significant
effect of acute prednisone administration (F 6.0; df 1, 21; p
0.02), but not of chronic treatment (F 0.2; df 1, 21; p 0.7)
(Table 2). There was no significant interaction between acute and
chronic treatment effects (F 0.2; df 1, 21; p 0.7). Further-
more, in the steroid group there were no significant correlations
of dose or duration of chronic prednisone treatment with mem-
ory performance under acute prednisone or placebo medication
(all p values 0.3, Pearson’s correlation).
For immediate recall, there was no significant effect of either
acute (F 0.2; df 1, 21; p 0.7) or chronic prednisone treat-
ment (F 0.3; df 1, 21; p 0.6), or their interaction (F 0.1;
df 1, 21; p 0.3) (Table 2).
MRI volumetry revealed no significant differences between
the steroid and nonsteroid groups for left or right hippocampal
volume, cerebral vault volume or global CSF volume (all p val-
Figure 1. Study design. Glucocorticoid levels weremanipulated at the time of retention testing (for details, seeMaterials and
Methods).
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ues  0.7) (Table 3). Furthermore, in the
steroid group there were no significant
correlations of dose or duration of chronic
prednisone treatment with left or right
hippocampal volume, cerebral vault vol-
ume or global CSF volume (all p values
0.1, Pearson’s correlation).
Salivary cortisol concentrations as-
sessed immediately before or 1 h after
acute prednisone or placebo administra-
tion on day 2 did not differ between the
two treatment groups (all p values  0.4)
(Table 3). Because of cross-reactivity of the
cortisol immunoassay with prednisone
and its active metabolite prednisolone, the
assay showed elevated levels 1 h after acute
prednisone medication compared with
cortisol levels before medication ( p 
0.01, for both treatment groups, paired t
tests). As the elimination half-life of pred-
nisolone is 2–4 h (Czock et al., 2005),
cross-reactivity with prednisolone 24 h af-
ter the last intake of prednisone is negligi-
ble. Therefore, the finding of similar corti-
sol levels between the treatment groups
immediately before the acute prednisone
administration, i.e., 24 h after the last ste-
roid application, indicates that the chronic
prednisone treatment did not result in a
lasting suppression of the hypothalamus–
pituitary–adrenal axis.
Discussion
The present study investigated whether
acute and reversible glucocorticoid effects
on memory retrieval contribute to the
memory deficits observed under chronic
glucocorticoid treatment. We therefore
manipulated glucocorticoid levels at the
time of memory retention testing in pa-
tients with rheumatoid arthritis who were treated either chroni-
cally with prednisone or without glucocorticoids. Whereas we
did not find evidence for harmful effects of the chronic pred-
nisone treatment on memory performance or hippocampal vol-
ume, acute administration of prednisone before retention testing
impaired delayed recall of verbal memory. These findings are in
line with the results of our previous studies indicating that an
acute elevation of glucocorticoid levels at the time of retention
testing impairs the retrieval of long-term spatial and contextual
memory in rats and declarative memory in healthy humans (De
Quervain et al., 1998, 2000; Roozendaal et al., 2003, 2004; Het et
al., 2005; Kuhlmann et al., 2005a,b). Also consistent with our
previous reports, we found a selective interference of acutely
elevated glucocorticoid levels with delayed, but not immediate
recall (De Quervain et al., 2000; Kuhlmann and Wolf, 2006).
Fromother studies, however, there is also evidence that glucocor-
ticoids can affect workingmemory (Wolf et al., 2001) and imme-
diate recall (Brunner et al., 2005), indicating that glucocorticoid
effects on short-term memory processes depend on the experi-
mental design (e.g., task or dose used). In addition to previous
findings, the present study shows that the acute glucocorticoid
effect on memory retrieval is also observed with the glucocorti-
coid prednisone. Furthermore, and also extending previous evi-
dence, the present findings indicate that the impairing effect of
pretesting administration of prednisone was not attributable to
state dependency (different glucocorticoid levels at learning and
retrieval) because glucocorticoid levels in both treatment groups
were also elevated during learning.
The findings of the present study are remarkable as they indi-
cate that declarative memory was not impaired 24 h after discon-
tinuation of the chronic glucocorticoid treatment, i.e., when
memory recall was tested under normalized glucocorticoid levels
after placebo administration. Previous studies have tested recov-
ery of memory function only after a substantial longer recovery
time (Brunner et al., 2005). The present findings indicate that
acute and direct glucocorticoid effects but not the history of
chronic glucocorticoid treatment played a role in inducingmem-
ory deficits. In the present study, we investigated patients treated
with low tomoderate doses of prednisone (between 5 and 15mg),
which are widely used in clinical practice (Lim and Conn, 2001;
Bijlsma et al., 2005). These doses, at the treatment durations in-
vestigated, did not induce any changes in hippocampal volume. It
is possible that memory deficits related to a history of chronic
treatment only appear at higher doses, or when associated with
clear effects on hippocampal morphology or volume. For exam-
ple, a previous study reported smaller hippocampal volumes and
Table 2. Effects of acute and chronic glucocorticoid treatment onmemory









Delayed recall 13.9 2.8 10.9 1.9 14.8 3.1 12.9 2.2
Immediate recall 9.1 0.8 8.8 0.9 7.9 0.9 8.6 1.0
Steroid group, Group with chronic prednisone medication; nonsteroid group, group without chronic glucocorticoid medication.
Table 3. Brain volumes and salivary cortisol concentrations
Steroid group Nonsteroid group p
Hippocampus right (cm3) 2.58 0.088 2.60 0.093 0.87
Hippocampus left (cm3) 2.49 0.079 2.47 0.084 0.89
Cerebral vault volume (cm3) 1171.7 37.4 1188.7 39.6 0.78
Global CSF volume (cm3) 163.3 11.5 158.0 12.2 0.78
Cort before placebo (nmol/L) 5.0 0.9 4.3 0.9 0.66
Cort before prednisone (nmol/L) 5.4 1.1 4.2 1.2 0.53
Cort 1 h after placebo (nmol/L) 4.2 1.1 5.7 1.2 0.42
Cort 1 h after prednisone (nmol/L) 20.6 3.5a 17.5 3.8a 0.60
Data are presented as mean SE. Steroid group, Group with chronic prednisone medication; nonsteroid group, group without chronic glucocorticoid
medication; Cort, cortisol concentration.
aThe cortisol immunoassay shows cross-reactivity with prednisone and its active metabolite prednisolone.
Table 1. Demographic and clinical data
Steroid group Nonsteroid group p
Females/males (n) 8/5 8/3 0.68
Age (years) 59.4 1.5 50.3 2.2 0.002
Education (years) 9.0 0.4 10.4 0.8 0.13
ESR 10.4 2.4 13.6 1.9 0.33
DAS28 3.1 0.5 3.4 0.3 0.56
RADAI 3.1 0.4 3.1 0.5 0.98
MADRS 5.7 2.0 5.2 1.3 0.84
Disease duration (months) 147.2 43.6 175.8 27.6 0.60
Dose of chronic prednisone medication (mg) 7.5 0.8
Duration of chronic prednisone medication (months) 63.7 11.8
Data are presented as mean SE. Steroid group, Group with chronic prednisone medication; nonsteroid group, group without chronic glucocorticoid
medication; ESR, Erythrocyte Sedimentation Rate; DAS28, Disease Activity Score; RADAI, Rheumatoid Arthritis Disease Activity Index; MADRS, Montgomery
Asberg Depression Scale.
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memory deficits in patients treated chronically with a mean dose
of 15.6 mg of prednisone for a mean duration of 92 months
compared with control patients not treated with corticosteroids
(Brown et al., 2004). However, in that study, no significant cor-
relation was found between hippocampal volume and memory
performance, suggesting that direct glucocorticoid effects on
memory performance also played an important role. Moreover,
another study investigating the effects of chronic prednisone
treatment (doses between 5 and 40 mg/d, durations between 1
and 15 years) found that the memory-impairing effect of pred-
nisone did not depend on dose or duration of the treatment,
further suggesting that direct glucocorticoid effects on memory
performance are important (Keenan et al., 1996). However, evi-
dence from Cushing’s disease patients indicated slow recovery of
both hippocampal volumes and memory functions after
treatment-induced lowering of cortisol levels (Starkman et al.,
1999, 2003), suggesting that, in this condition, the memory im-
pairment may be related to the smaller hippocampi. However,
alternative explanations are possible, as previous evidence indi-
cates that memory deficits that occur after lesioning the CA3
region of the hippocampus in rats are not caused by the structural
loss, but rather related to elevated glucocorticoid levels because of
a lesion-induced disinhibition of hypothalamus–pituitary–adre-
nal axis activity (Roozendaal et al., 2001). These deficits could be
blocked by a pharmacological inhibition of glucocorticoid syn-
thesis before memory retrieval testing. Other findings in rats in-
dicated that an attenuation of glucocorticoid levels at the time of
memory assessment prevented chronic stress-induced impair-
ments in spatial memory (Wright et al., 2006), under conditions
known to induce atrophy of hippocampal neurons (Conrad et al.,
1999). Altogether, it is likely that acute glucocorticoid effects on
memory retrieval, even in the presence of hippocampal atrophy,
participate in inducing memory deficits associated with chroni-
cally elevated glucocorticoid levels.
In summary, although the present study investigating rheu-
matoid arthritis patients treated chronically with low to moder-
ate doses of prednisone did not provide evidence for harmful
effects onmemory performance related to the chronic treatment,
elevated glucocorticoid levels at the time of retention testing in-
ducedmemory retrieval impairment. These findings suggest that
memory deficits observed in conditions with chronically elevated
glucocorticoid levels may result, at least in part, from acute and
reversible glucocorticoid effects on memory retrieval.
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